Chemed(US:CHE)2024-02-28 18:42Financial Data and Key Metrics Changes - Roto-Rooter generated quarterly revenue of $235.9 million in Q4 2023, a decrease of 1.1% compared to the prior year quarter [2] - Adjusted EBITDA in Q4 2023 totaled $64.9 million, a decrease of 6.4% compared to the prior year quarter, with an adjusted EBITDA margin of 27.5%, down 154 basis points from the prior year [3] - VITAS net revenue was $350 million in Q4 2023, an increase of 13.6% compared to the prior year period, driven by an 11.0% increase in days-of-care and a 2.3% increase in Medicare reimbursement rates [76] Business Line Data and Key Metrics Changes - Roto-Rooter branch commercial revenue totaled $56.8 million in Q4 2023, a decrease of 7.9% over the prior year, while residential revenue increased by 2% to $162.5 million [2] - VITAS admissions increased by 7% in Q4 2023, with nursing home admissions up 1.7%, assisted facility admissions up 16.4%, hospital-directed admissions up 0.5%, and home-based patient admissions up 15.2% compared to the prior year [12] - Average Daily Census (ADC) for VITAS was 19,352 patients in Q4 2023, an increase of 11% compared to the prior year [10] Market Data and Key Metrics Changes - Roto-Rooter experienced an 18.7% decline in call volume compared to the prior year quarter, with a 13% decline when excluding a significant weather impact from the previous year [73] - The company anticipates improving demand trends starting in Q2 2024, reflecting a stabilization in consumer sentiment [74] Company Strategy and Development Direction - VITAS aims for revenue growth of 9% to 9.8% in 2024, with an EBITDA margin prior to Medicare Cap estimated at 17.8% to 18.3% [4] - Roto-Rooter is expected to achieve full-year 2024 revenue growth of 3.5% to 4%, with a focus on leveraging competitive advantages in service offerings [6] - The company is committed to a balanced approach in managing Medicare Cap and maintaining strong relationships with hospital partners [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of volume growth for VITAS, citing favorable demographics and increased awareness of hospice benefits [22] - The company acknowledged ongoing economic headwinds affecting consumer spending but remains optimistic about market share expansion and operational efficiencies [60] - Management noted that the fourth quarter typically sees a spike in VITAS margins due to reimbursement rate increases, with expectations for continued margin improvement in 2024 [96] Other Important Information - The retention bonus program ended in June 2023, but the company continued to expand its workforce and patient capacity in the latter half of 2023 [49] - Adjusted EBITDA margin for VITAS in Q4 2023 was 23.7%, significantly improved due to various operational efficiencies and changes in PTO policies [78] Q&A Session Summary Question: What gives confidence in VITAS's volume growth? - Management believes that aging demographics and earlier access to hospice care will support sustainable volume growth beyond 2024 [22] Question: How does the company view the future of Roto-Rooter? - Management sees the current economic challenges as a temporary phase, with expectations for recovery and market share growth as conditions improve [36][40] Question: What is the outlook for margins in VITAS and Roto-Rooter? - VITAS is expected to see margins in the range of 17.8% to 18.3% for 2024, with potential for gradual improvement [31][45] - Roto-Rooter anticipates methodical margin improvements as top-line growth stabilizes [48]